Aerosolization of novel nitric oxide donors selectively reduce pulmonary hypertension

Critical Care Medicine

Volumn 26, Issue 8, 1998, Pages 1390-1396

  Brilli, Richard J ^a   Krafte Jacobs, Brian ^a   Smith, Daniel J ^b   Passerini, Daniel ^b   Moore, Lori ^a   Ballard, Edgar T ^a  

^a CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^b UNIVERSITY OF AKRON   (United States)

Author keywords

Intratracheal; Nitric oxide donor; NO nucleophile adduct; NONOate; Pulmonary circulation; Pulmonary hypertension; Respiratory failure; Tertiary amine

Indexed keywords

15 HYDROXY 11ALPHA,9ALPHA EPOXYMETHANOPROSTA 5,13 DIENOIC ACID; 2 (DIMETHYLAMINO)ETHYLPUTREANINE NONOATE; ETHYLPUTREANINE NONOATE; NITRIC OXIDE; NITRIC OXIDE DONOR; UNCLASSIFIED DRUG;

ACUTE RESPIRATORY FAILURE; AEROSOL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERIAL GAS; ARTICLE; CONTROLLED STUDY; HEART ATRIUM PRESSURE; HEART INDEX; HEART OUTPUT; INHALATIONAL DRUG ADMINISTRATION; LUNG ARTERY PRESSURE; LUNG VASCULAR RESISTANCE; MALE; MEAN ARTERIAL PRESSURE; NONHUMAN; PRIORITY JOURNAL; PROSPECTIVE STUDY; PULMONARY HYPERTENSION; SWINE;

EID: 0031880381     PISSN: 00903493     EISSN: None     Source Type: Journal    
DOI: 10.1097/00003246-199808000-00026     Document Type: Article

References (48)

1. Radermacher P, Santak P, Becker H, et al: Prostaglandin E1 and nitroglycerin reduce pulmonary capillary pressure but worsen V/Q distribution in patients with adult respiratory distress syndrome. Anesthesiology 1989; 70:601-609
2. Kinsella JP, Abman SH: Recent developments in the pathophysiology and treatment of persistent pulmonary hypertension of the newborn. J Pediatr 1995; 126:853-864
3. Robert JD, Lang P, Bigatello LM, et al: Inhaled nitric oxide in congenital heart disease. Circulation 1993; 87:447-453
4. Moncada S, Palmer RMJ, Higgs EA: Nitric oxide: Physiology, pathophysiology, and pharmacology. Pharmacol Rev 1991; 43:109-141
5. Palmer RMJ, Ferrige AG, Moncada S: Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor. Nature 1987; 327:524-526
6. Roberts JD, Chen TY, Kawai N, et al: Inhaled nitric oxide reverses pulmonary vasoconstriction in the hypoxic and acidotic newborn lamb. Circ Res 1993; 72:246-254
7. Nelin L, Moshin C, Sasidharan T, et al: The effect of inhaled nitric oxide on the pulmonary circulation of the neonatal pig. Pediatr Res 1994; 35:20-24
8. Etches P, Finer K, Barrington A, et al: Nitric oxide reverses acute hypoxic pulmonary hypertension in the newborn piglet. Pediatr Res 1994; 35:15-19
9. Rossaint R, Falke KJ, Lopez F, et al: Inhaled nitric oxide for the adult respiratory distress syndrome. N Engl J Med 1993; 328:399-405
10. Abman SH, Griebel JL, Parker DK, et al: Acute effects of inhaled nitric oxide in children with severe hypoxemic respiratory failure. J Pediatr 1994; 124:881-884
11. Rossaint R, Gerlach H, Schmidt-Ruhnke H, et al: Efficacy of inhaled nitric oxide in patients with severe ARDS. Chest 1995; 107:1107-1115
12. Day RW, Guarin M, Lynch JM, et al: Inhaled nitric oxide in children with severe lung disease: Results of acute and prolonged therapy with two concentrations. Crit Care Med 1996; 24:215-221
13. Beghetti M, Habre W, Friedli B, et al: Continuous low dose inhaled nitric oxide for treatment of severe pulmonary hypertension after cardiac surgery in paediatric patients. Br Heart J 1995; 73:65-68
14. Roberts JD, Fineman JR, Morin FC, et al: Inhaled nitric oxide and persistent pulmonary hypertension of the newborn. N Engl J Med 1997; 336:605-610
15. Neonatal Inhaled Nitric Oxide Study Group: Inhaled nitric oxide in fullterm and nearly full-term infants with hypoxic respiratory failure. N Engl J Med 1997; 336:597-604
16. Hoffman GM, Ross GA, Day SE, et al: Inhaled nitric oxide reduces the utilization of extracorporeal membrane oxygenation in persistent pulmonary hypertension of the newborn. Crit Care Med 1997; 25:352-359
17. Hess D, Kacmarek RM, Ritz R, et al: Inhaled nitric oxide delivery systems: A role for respiratory therapists. Respiratory Care 1995; 40:702-705
18. Betit P, Adatia I, Benjamin P, et al: Inhaled nitric oxide: Evaluation of a continuous titration delivery technique for infant and manual ventilation. Respiratory Care 1995; 40:706-715
19. Wessel DL, Adatia I, Thompson JE, et al: Delivery and monitoring of inhaled nitric oxide in patients with pulmonary hypertension. Crit Care Med 1994; 22:930-938
20. Goldman AP, Tasker RC, Haworth SG, et al: Four patterns of response to inhaled nitric oxide for persistent pulmonary hypertension of the newborn. Pediatrics 1996; 98:708-713
21. Lavoie A, Hall JB, Olson DM, et al: Life-threatening effects of discontinuing inhaled nitric oxide in severe respiratory failure. Am J Respir Crit Care Med 1996; 153:1985-1987
22. Morley D, Keefer LK: Nitric oxide/ Nucleophile complexes: A unique class of nitric oxide-based vasodilators. J Cardiovasc Pharmacol 1993; 22: S3-S9
23. Morley D, Maragos CM, Zhang XY, et al: Mechanism of vascular relaxation induced by the nitric oxide (NO)/nucleophile complexes, a new class of NO-based vasodilators. J Cardiovasc Pharmacol 1993; 21:670-676
24. Diodati JG, Quyyumi AA, Keefer LR: Complexes of nitric oxide with nucleophiles as agents for the controlled biological release of nitric oxide: Hemodynamic effect in the rabbit. J Cardiovasc Pharmacol 1993; 22:287-292
25. Maragos CM, Morley D, Wink DA: Complexes of NO with nucleophiles as agents for the controlled release of nitric oxide. Vasorelaxant effects. J Med Chem 1991; 34:3242-3247
26. Vanderford PA, Wong J, Chang R, et al: Diethylamine/nitric oxide (NO) adduct, an NO donor, produces potent pulmonary and systemic vasodilation in intact newborn lambs. J Cardiovasc Pharmacol 1994; 23:113-119
27. Disalvo E: Permeability of water and polar solutes in lipid bilayers. Adv Colloid Interface Sci 1988; 29:141-170
28. Hampl V, Tristani-Firouzi M, Hutsell TC, et al: Nebulized nitric oxide/nucleophile adduct reduces chronic pulmonary hypertension. Cardiovasc Res 1996; 31:55-62
29. Brilli R, Krafte-Jacobs B, Smith D, et al: Intratracheal instillation of a novel nitric oxide/nucleophile adduct selectively reduces pulmonary hypertension. J Appl Physiol 1997; 83: 1968-1975
30. Jobe A, Ikegami M, Jacobs H, et al: Surfactant and pulmonary blood flow distributions following treatment of premature lambs with natural surfactant. J Clin Invest 1984; 73:848-856
31. Gilliard N, Richman PM, Merritt TA, et al: Effect of volume and dose on the pulmonary distribution of exogenous surfactant administration to normal rabbits or to rabbits with oleic acid lung injury. Am Rev Respir Dis 1990; 141:743-747
32. Perring S, Summers Q, Fleming J, et al: A new method of quantification of the pulmonary regional distribution of aerosols using combined CT and SPECT and its application to nedocromil sodium administered by metered dose inhaler. Br J Radiol 1994; 67:46-53
33. Frostell CG, Blomqvist H, Hedenstierna G, et al: Inhaled nitric oxide selectively reverses human hypoxic pulmonary vasoconstriction without causing systemic vasodilation. Anesthesiology 1993; 78:427-435
34. Miller OI, Tang SF, Keech A, et al: Rebound pulmonary hypertension on withdrawal from inhaled nitric oxide. Lancet 1995; 346:51-52
35. Kiff RJ, Moss DW, Moncada S: Effect of nitric oxide gas on the generation of nitric oxide by isolated blood vessels: Implication for inhalation therapy. Br J Pharmacol 1994; 113:496-498
36. Theodore J, Robin ED, Gaudio R, et al: Transalveolar transport of large polar solutes (sucrose, inulin, and dextran). Am J Physiol 1975; 229:989-996
37. Paula S, Volkov A, Van Hoek A, et al: Permeation of protons, potassium ions, and small polar molecules through phospholipid bilayers as a function of membrane thickness. Biophys J 1996; 70:339-348
38. Peck K, Ghanem A, Higuchi W: Hindered diffusion of polar molecules through and effective pore radii estimates of intact and ethanol treated human epidermal membrane. Pharm Res 1994; 11:1306-1314
39. Hess D: Inhaled bronchodilators during mechanical ventilation: Delivery techniques, evaluation of response, and cost effectiveness. Respiratory Care 1994; 39:105-122
40. Johnston C: Endotracheal drug delivery. Pediatr Emerg Care 1992; 8:94-97
41. Jasani MS, Nadkarni VM, Finkelstein, et al: Effects of different techniques of endotracheal epinephrine administration in pediatric porcine hypoxichypercarbic cardiopulmonary arrest. Crit Care Med 1994; 22:1174-1180
42. Henry MD, Rebello CM, Ikegami M, et al: Ultrasonic nebulized in comparison with instilled surfactant treatment of preterm lambs. Am J Respir Crit Care Med 1996; 154:366-375
43. Cohen SS: What do polyamines do? Nature 1978; 274:209-214
44. Seiler N, Bolkenius FN, Rennert OM: Interconversion, catabolism, and elimination of the polyamines. Medical Biology 1981; 59:334-346
45. Nishimura M, Hess D, Kacmarek RM, et al: Nitrogen dioxide production during mechanical ventilation with nitric oxide in adults. Effects of ventilator internal volume, air versus nitrogen dilution, minute ventilation, and inspired oxygen fraction. Anesthesiology 1995; 82:1246-1254
46. Gong H: Health effects of air pollution - A review of clinical studies. Clin Chest Med 1992; 13:201-214
47. Stephens RJ, Freeman G, Evans MJ: Early response of lungs to low levels of nitrogen dioxide. Light and electron microscopy. Arch Environ Health 1972; 24:160-179
48. Rasmussen T, Kjaergarrd S, Tarp U, et al: Delayed effects of NO2 exposure on alveolar permeability and glutathione peroxidase in healthy humans. Am Rev Respir Dis 1992; 146:654-659